Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations

Những quyển sách tương tự

• Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
  Bằng: Cui, Shaohua, et al.
  Được phát hành: (2016)
• Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
  Bằng: Cui, Shaohua, et al.
  Được phát hành: (2016)
• The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma
  Bằng: Infarinato, Nicole R., et al.
  Được phát hành: (2015)
• ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
  Bằng: Ye, Mingxiang, et al.
  Được phát hành: (2016)
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors
  Bằng: Cui, Shaohua, et al.
  Được phát hành: (2016)